ERBB2 and idiopathic pulmonary fibrosis: After treating IPF lung fibroblasts with Lapatinib, decreased p-HER2 levels were observed in a dose-dependent manner (Fig. 7 G), suggesting that Lapatinib was effective in blocking HER2 signaling in IPF lung fibroblasts.